Comparison of Efficacy and Safety of Generic Plerixafor Vs Original Plerixafor in the Mobilization of Myeloma Patients

Sevindik, Omur Gokmen; Bilgen, Hülya; Serin, Istemi; Melek, Elif; Karakuş, Volkan; ÇERÇİ, Kübra; Mutlu, Yasa Gul; Aydın, Berrin Balık; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül

doi:10.1182/blood-2022-168558

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plerixafor is now offpatent and has been made as a generic, but the generic formulation is not yet widely available. Initial studies of the generics have shown that their efficacy and safety are comparable to the original [38,39] .…”

Section: Optimal Mobilization Regimenmentioning

confidence: 99%

Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients

Fitzsimons,

Hagen

2024

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Multiple myeloma is a neoplastic disorder of plasma cells typically afflicting older individuals. Despite significant improvements in induction therapy and outcomes for transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients, autologous stem cell transplant (ASCT) remains the standard of care for consolidation in transplant-eligible NDMM. Consequently, the optimal approach to stem cell mobilization remains critical. In this manuscript, we outline key updates to stem cell mobilization in NDMM patients. We describe the optimal number of cycles of induction prior to mobilization, emphasizing the need to balance the benefit of achieving improved depth of response by giving additional cycles of pre-transplant induction with the impact on stem cell yields. Additionally, we review ideal timing between the end of induction and initiation of mobilization to facilitate both a minimization of time off therapy as well as better communication and work flow between community providers and transplant centers. We also review different stem cell mobilization regimens with and without upfront CXCR4 inhibitors to optimize stem cell yields while considering both clinical outcomes and cost of care. Finally, we review optimal yields of CD34+ hematopoietic stem cells to minimize toxicity for ASCT and also consider optional utilization of stem cells for both salvage second ASCT and stem cell boosts for poor marrow function.

show abstract

Section: Optimal Mobilization Regimenmentioning

confidence: 99%

Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients

Fitzsimons,

Hagen

2024

J Cancer Metastasis Treat

View full text Add to dashboard Cite

show abstract

Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients

Yuan,

Chang,

Kim

et al. 2024

Transfusion

View full text Add to dashboard Cite

BackgroundPlerixafor is an adjunct peripheral blood stem cell (PBSC) mobilization agent with well‐demonstrated safety and efficacy. The routine use of the originator brand drug (Mozobil) has been limited by cost. This retrospective study was conducted to compare the mobilization efficacy of a lower‐cost generic plerixafor and Mozobil in multiple myeloma (MM) patients.Study Design and MethodsThe study included two near‐concurrent cohorts of MM patients mobilized with brand (n = 64) or generic (n = 61) plerixafor in addition to filgrastim. Collection and early engraftment outcomes were compared.ResultsThe two cohorts had comparable distributions of sex, age, and weight. Previous treatment histories and proportions of upfront versus just‐in‐time plerixafor use were similar. There was no significant difference in their median overall cumulative total yield (106 CD34+ cells/kg) (brand, 5.91; generic, 5.80; p = .51). However, the generic cohort had a significantly higher median yield after the first dose (4.79 vs. 3.78, p = .03), and consequently lower median numbers of plerixafor doses (p = .001) and collection days (p = .002). Only 31.1% of patients in the generic arm required more than one dose versus 59.4% of patients in the brand arm (p = .006).All transplanted patients in the brand and generic arms (90.6% and 85.2% respectively, p = .42) achieved engraftment. There was no significant difference in their median times to platelet and neutrophil engraftment, nor their transfusion requirements during the first 30 days post‐transplant.ConclusionThe generic plerixafor produced comparable cumulative collection yields and early engraftment outcomes as Mozobil, but fewer doses and collection days were needed to reach collection goal.

show abstract

Comparison of Efficacy and Safety of Generic Plerixafor Vs Original Plerixafor in the Mobilization of Myeloma Patients

Cited by 2 publications

References 0 publications

Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients

Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients

Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients

Contact Info

Product

Resources

About